

The European Molecular Genetics Quality Network

Certificate of Participation 2015 (Autumn)

This is to certify that

CIDEGEN

Participated in 2015 (Autumn) in the following European Molecular Genetics Quality Network (EMQN) external quality assessment schemes:

Scheme	Genotyping	Interpretation	Clerical	Result
Lung Cancer (NSCLC)	1.78	1.13	1.50	Satisfactory

The laboratory participated in 1 scheme and passed 1 of them. The detailed performance data are given on the Individual Laboratory Report (ILR). When viewing the certificates, you should ensure that 1 scheme is listed.

Key: NRS: No Results Submitted WFS: Withdrew From Scheme Signed by: Prof. David Barton Dr. Simon Patton **EMQN** Chairman **EMQN** Director

EMQN is a not for profit organisation which provides external quality assessment schemes for genetic testing laboratories. EMQN is a UKAS accredited provider of EQA services and is based at the Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK.



The European Molecular Genetics Quality Network

Certificate of Participation 2017

This is to certify that

Centro Internacional de Estudios en Genética Humana CIDEGEN

Participated in 2017 in the following European Molecular Genetics Quality Network (EMQN) external quality assessment schemes:

Scheme	Genotyping	Interpretation	Clerical	Result
Colorectal Cancer (Sporadic)	2.00	2.00	2.00	Satisfactory

The laboratory participated in 2 schemes and passed 2 of them. The detailed performance data are given on the Individual Laboratory Report (ILR). When viewing the certificates, you should ensure that 2 schemes are listed.

Key:	> Scheme Mean	< Scheme Mean	Poor performance
	NRS: No Results Subm WFS: Withdrew From S		
	Signed by:		S.Marbetton
		Prof. David Barton EMQN Chairman	Dr. Simon Patton EMQN Director

EMQN is a not for profit organisation which provides external quality assessment schemes for genetic testing laboratories. EMQN is a UKAS accredited provider of EQA services and is based at the Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK.



The European Molecular Genetics Quality Network

Certificate of Participation 2018

This is to certify that

CIDEGEN

Participated in 2018 in the following European Molecular Genetics Quality Network (EMQN) external quality assessment schemes:

Scheme	Genotyping	Interpretation	Clerical	Result
BRCA (Full scheme)	2.00	1.60	2.00	Satisfactory
MELANOMA	1.70	2.00	1.47	Poor
POSTNATAL CONSTITUTIONAL CNV DETECTION [ARRAY]	2.00	1.50	2.00	Satisfactory

The laboratory participated in 3 schemes and passed 2 of them. The detailed performance data are given on the Individual Laboratory Report (ILR). When viewing the certificates, you should ensure that 3 schemes are listed.

Key:	> Scheme Mean	< Scheme Mean	Poor performance
	NRS: No Results Subm WFS: Withdrew From		
	Signed by:		Sman bitton
		Prof. David Barton EMQN Chairman	Dr. Simon Patton EMQN Director

EMQN is a not for profit organisation which provides external quality assessment schemes for genetic testing laboratories. EMQN is a UKAS accredited provider of EQA services and is based at the Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK.





EMQN Office Manchester Centre for Genomic Medicine, 6th Floor, St Mary's Hospital, Hathersage Road, Manchester M13 9WL, United Kingdom. Tel: +44 161 276 6741 Fax: +44 161 276 6606 Email: office@emqn.org

INDIVIDUAL LABORATORY REPORT (ILR) - Lab 1430

SCHEME:

Г

BRCA (Full scheme)

SEASON: 2018

Case 1		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0.00)
Interpretation	2.00	No deduction (0.00)
Patient identifiers and clerical	2.00	Comment: Failure to indicate two signatures (0.00)
accuracy		
		Comment: No pagination (eg X of Y) (0.00)

Case 2		
Assessment Category	Score ¹	Comments (& deductions ²)
Genotyping	2.00	No deduction (0.00)
Interpretation	2.00	No deduction (0.00)
Patient Identifiers and Clerical Accuracy	2.00	Comment: Failure to indicate two signatures (0.00)
		Comment: No pagination (eg X of Y) (0.00)

Case 3		
Assessment Category Score ¹		Comments (& deductions ²)
Genotyping	2.00	No deduction (0.00)
Interpretation 0.80 Missing effect of variant on patient (risk modification?) (0.20)		Missing effect of variant on patient (risk modification?) (0.20)
		The patient consented for targeted testing only but you reported a full panel analysis, which is considered as over testing and potentially harmful to the patient (1.00)
Patient Identifiers and Clerical Accuracy	2.00	Comment: Failure to indicate two signatures (0.00)
		Comment: No pagination (eg X of Y) (0.00)

Published: 20 July 2018

© Copyright EMQN. No part of this document may be copied, distributed or published in any form without the written permission of the EMQN

Page 1 of 2

¹ Maximum score is 2.00

² Deductions from the maximum score

^a Green >= Scheme mean, Orange < Scheme mean, Red Poor performance. NRS no results submitted. WDS withdrew from scheme

General Comments	Thank you for participating in this year's EQA scheme. We look forward to you joining us in the 2019		
	General Comments	scheme - registration to participate will be available from September 2018 via the EMQN website.	

SUMMARY OF YOUR PERFORMANCE IN THIS SCHEME

Assessment Category	Performance ³ (mean score)
Genotyping	2.00
Interpretation	1.60
Patient Identifiers and Clerical Accuracy	2.00
Scheme result (SATISFACTORY or POOR)	SATISFACTORY

NOTE: The results above are subject to change depending on the results of the appeals process. The final results will be displayed on the EMQN certificate of participation

Report approved and authorised by Simon Patton (20 July 2018) on behalf of EMQN. Signed:



Published: 20 July 2018

© Copyright EMQN. No part of this document may be copied, distributed or published in any form without the written permission of the EMQN

Page 2 of 2

¹ Maximum score is 2.00

² Deductions from the maximum score

Scheme mean, Orange < Scheme mean, Red Poor performance.
NRS no results submitted. WDS withdrew from scheme





EMQN Office Manchester Centre for Genomic Medicine, 6th Floor, St Mary's Hospital, Hathersage Road, Manchester M13 9WL, United Kingdom. Tel: +44 161 276 6741 Fax: +44 161 276 6606 Email: office@eman.org

INDIVIDUAL LABORATORY REPORT (ILR) - Lab 1430

SCHEME:

POSTNATAL CONSTITUTIONAL CNV DETECTION [ARRAY]

SEASON: 2018

Case 1		
Assessment Category Score ¹		Comments (& deductions ²)
Genotyping	2.00	Correct result (0)
Interpretation	1.00	Comment(s) with deduction (1) The first sentence in the Summary section is incorrect (=-1.0 Deduction)
Patient Identifiers and Clerical Accuracy	2.00	The practical resolution should be given in the report (0)
		The pagination should be given on the report e.g. Page 1 of 1 (0)

Case 2			
Assessment Category	Score ¹	Comments (& deductions ²)	
Genotyping	2.00	Non-significant ISCN error. (0)	
Interpretation	2.00	The list of genes is unhelpful - only the clinically relevant genes should be discussed (0)	
Patient Identifiers and Clerical Accuracy	2.00	2.00 The pagination should be given on the report e.g. Page 1 of 1. (0)	
	Thank you	Thank you for participating in Postnatal constitutional CNV detection EQA scheme. Registratio	
General Comments	are now open for participation in our 2019 scheme. We look forward to welcoming you bac		

SUMMARY OF YOUR PERFORMANCE IN THIS SCHEME

Assessment Category

Genotyping

Interpretation

Patient Identifiers and Clerical Accuracy

Scheme result (SATISFACTORY or POOR)



Report approved and authorised by Simon Patton (26 October 2018) on behalf of EMQN. Signed:



This report is provisional pending the outcome of the appeals process

Page 1 of 1

¹ Maximum score is 2.00

² Deductions from the maximum score

^a Green >= Scheme mean, Orange < Scheme mean, Red Poor performance. NRS no results submitted. WDS withdrew from scheme